{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:33:05Z","timestamp":1790260385151,"version":"4.1.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0188103","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T13:33:11Z","timestamp":1511271191000},"page":"e0188103","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2431-2511","authenticated-orcid":true,"given":"Maria","family":"K\u00f6ping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa","family":"Shehata-Dieler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cebulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Rak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Oder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"M\u00fcntze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nordbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"issue":"4","key":"ref1","first-page":"338","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"RJ Desnick","year":"2003"},{"key":"ref2","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (DGN) (2013): Interdisziplin\u00e4re Leitlinie f\u00fcr die Diagnose und Therapie des Morbus Fabry."},{"issue":"1","key":"ref3","first-page":"3733","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"M Biegstraaten","year":"2015"},{"issue":"1\u20132","key":"ref4","first-page":"5","article-title":"Fabry's disease","volume":"344","author":"R El-Abassi","year":"2014"},{"issue":"3","key":"ref5","first-page":"249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"PJ Meikle","year":"1999"},{"issue":"26","key":"ref6","first-page":"440","article-title":"Fabry disease-often seen, rarely diagnosed","volume":"106","author":"B Hoffmann","year":"2009"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*","volume":"79","author":"M Spada","year":"2006","journal-title":"The American Journal of Human Genetics"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"W-L Hwu","year":"2009","journal-title":"Hum. Mutat."},{"issue":"11","key":"ref9","first-page":"750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"KD MacDermot","year":"2001"},{"issue":"1","key":"ref10","first-page":"65","article-title":"Fabry disease","volume":"122","author":"R Schiffmann","year":"2009"},{"key":"ref11","first-page":"10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"DP Germain","year":"2002"},{"key":"ref12","first-page":"33","article-title":"Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females","volume":"92","author":"G Conti","year":"2003"},{"issue":"10","key":"ref13","first-page":"1433","article-title":"Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy","volume":"254","author":"A Palla","year":"2007"},{"issue":"5","key":"ref14","first-page":"359","article-title":"Otologic histopathology of Fabry's disease","volume":"98","author":"PA Schachern","year":"1989"},{"issue":"2","key":"ref15","first-page":"345","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"R Schiffmann","year":"2006"},{"issue":"4","key":"ref16","first-page":"563","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"JE Wraith","year":"2008"},{"issue":"5","key":"ref17","first-page":"1547","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"DP Germain","year":"2007"},{"issue":"2","key":"ref18","first-page":"153","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"DA Hughes","year":"2008"},{"issue":"2","key":"ref19","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002"},{"key":"ref20","first-page":"253","author":"M Dolgin","year":"1994"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1186\/s12969-015-0041-9","article-title":"Early detection of sensorineural hearing loss in Muckle-Wells-syndrome","volume":"13","author":"JB Kuemmerle-Deschner","year":"2015","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"ref22","first-page":"48","article-title":"Presbycusis Values in Relation to Noise Induced Hearing Loss","volume":"6","author":"A Spoor","year":"2009"},{"key":"ref23","author":"C Mathers","year":"2000"},{"issue":"9","key":"ref24","first-page":"654","article-title":"Hearing loss in Fabry disease: data from the Fabry Outcome Survey","volume":"36","author":"S Hegemann","year":"2006"},{"issue":"3","key":"ref25","first-page":"185","article-title":"H\u00f6rst\u00f6rungen bei Morbus Fabry","volume":"55","author":"A Limberger","year":"2007"},{"key":"ref26","article-title":"Fabry disease. Perspectives from 5 years of FOS","author":"A Keilmann","year":"2006"},{"key":"ref27","unstructured":"Wanner C (op. 2004): Morbus Fabry. Klinik, Diagnostik und Therapie. Bremen [etc.]: UNI-MED (Uni-Med science)."},{"issue":"6","key":"ref28","first-page":"412","article-title":"Fabry's disease: otoneurologic findings in twelve members of one family","volume":"115","author":"D Vibert","year":"2006"},{"issue":"8","key":"ref29","first-page":"787","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"D Hajioff","year":"2003"},{"issue":"2","key":"ref30","first-page":"87","article-title":"Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy","volume":"30","author":"B Sergi","year":"2010"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0188103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:50:22Z","timestamp":1588971022000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0188103"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Martines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0188103","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}